In-Licensing China Biotech Assets: Strategic Guide 2026

Why In-License from China Now?

The global pharmaceutical innovation map has been fundamentally redrawn. For three decades, China was the world's contract manufacturer — the place where active pharmaceutical ingredients were made cheaply and in volume. Today, that story is obsolete. China has undergone a structural innovation reversal, transitioning from a generic copier into a world-class originator of novel therapeutic assets. Its biotech ecosystem — anchored in Shanghai, Beijing, Suzhou, and Shenzhen — now rivals Boston and London in the density of clinical-stage innovation.

The numbers tell the story plainly. In 2025, Chinese biotech companies signed $138.8 billion of out-licensing deals (PharmCube), and 40% of all assets in-licensed by big pharma that year came from a Chinese licensor (IQVIA). Increasingly these are clinically validated assets licensed to Pfizer, AstraZeneca, GSK, Roche, AbbVie, and Regeneron. We track the full picture in our China biotech outbound licensing tracker.

The most dramatic indicator of China's innovation leadership is its dominance in Antibody-Drug Conjugate chemistry. China-origin ADCs feature in many of the largest recent licensing deals — a molecule class that has produced some of the most valuable oncology deals of the last five years — and across all modalities, China-origin assets made up 51% of big pharma licensing deals with at least $50 million upfront through Q3 2026 (J.P. Morgan). Kelun-Biotech, MediLink Therapeutics, and Duality Biotherapeutics have become household names in oncology business development.

For Western BD executives, the urgency is real: the window for licensing premium Chinese assets at reasonable valuations is closing. Early movers gained structural competitive advantages: Summit Therapeutics licensed ivonescimab from Akeso in 2022, and Merck licensed a portfolio of ADCs from Kelun-Biotech the same year, including sacituzumab tirumotecan. As NMPA data becomes increasingly FDA-accepted and deal precedents pile up, Chinese licensors are becoming far more sophisticated in their negotiating positions. The "China discount" on upfront payments is narrowing with each successive headline deal.

$138.8B in China out-licensing deals in 2025

Chinese biotech companies signed $138.8 billion of out-licensing deals in 2025, most of it in milestones rather than upfront cash, and 2026 had already reached $139.4 billion by early October — a scale that would have been unthinkable a decade ago and now defines China as an essential source of global pipeline innovation.

PharmCube; IQVIA

Where to Find Chinese Biotech Assets

Sourcing Chinese biotech assets requires a multi-channel approach that combines global conference presence, database intelligence, and in-country relationship networks. The best deals are almost never found through a cold database search alone — they come from trusted local intermediaries and established conference relationships.

Conferences: Where Deals Begin

J.P. Morgan Healthcare Conference

San Francisco, January. The global biotech dealmaking epicenter. Chinese companies now send large delegations — often their most senior BD and C-suite executives — specifically to initiate Western licensing conversations.

BIO International Convention

June, rotating US cities. The largest biotech partnering event globally. The BIO One-on-One Partnering system enables targeted meetings with Chinese companies across all therapeutic areas.

ChinaBio Partnering Forum

Held annually in China. The most concentrated event specifically for China cross-border licensing. Attendance signals serious licensing intent from Chinese companies.

CPHI China

Shanghai, June. Pharmaceutical manufacturing and supply chain focus. Critical for identifying CMC capabilities, CDMO relationships, and manufacturing transferability of Chinese assets.

Databases and Intelligence Sources

Commercial databases are essential for systematic pipeline scouting. Cortellis Drug Intelligence (Clarivate) provides the most comprehensive tracking of Chinese clinical-stage assets, deal transactions, and patent activity. Evaluate Pharma is indispensable for commercial forecasting and valuation benchmarking. For IP-level intelligence, the CNIPA (China National Intellectual Property Administration) patent database provides direct access to Chinese filing activity — often revealing innovation months before it appears in Western databases.

China's National Key R&D Program (NKP) is an underutilized intelligence source for Western BD teams. The NKP tracks government-funded innovation across Chinese universities and institutes — often the earliest signal of a breakthrough technology before it has been spun out into a commercial entity. Monitoring NKP grants in oncology, immunology, and metabolic disease can give an early signal of commercially interesting programs.

Local Networks and In-Country Presence

No database replaces the value of an in-country BD network. Hong Kong functions as the strategic gateway hub between mainland China and the Western financial and legal ecosystem. Most major Chinese biotech companies have Hong Kong offices, and many use Hong Kong holding structures for their licensing arrangements. Being present in Hong Kong — or having trusted partners there — dramatically accelerates deal access.

In mainland China, Shanghai (Zhangjiang Pharma Valley) and Beijing (Zhongguancun Life Sciences Park) are the primary innovation hubs. Local BD representatives with deep relationships in these ecosystems can access pre-publication pipeline data, introductions to company founders, and early-stage partnering opportunities that never appear at international conferences. Vision Lifesciences maintains proprietary scouting networks in Shanghai, Beijing, and Hong Kong — enabling access to assets well before they enter formal out-licensing processes.

Social channels matter more than Western BD executives typically expect. WeChat biotech communities and Chinese biotech investor networks (including family offices and healthcare-focused VCs in the Cayman/BVI structure space) are active deal origination channels. A credible WeChat presence within the Chinese biotech BD community signals serious engagement and often opens doors that formal outreach cannot.

Therapeutic Areas with the Strongest China Pipelines

Not all Chinese biotech innovation is created equal. Five therapeutic areas stand out as exceptional sources of licensable, globally competitive assets — each with distinct scientific advantages rooted in China's unique patient population, manufacturing capabilities, or research focus. For a comprehensive analysis of available assets, see our China biotech licensing opportunities report.

ADC (Antibody-Drug Conjugates)

A leading global source. China-origin ADCs feature in many of the largest recent licensing deals. Kelun-Biotech, MediLink, and Duality Bio have set the benchmark for next-generation linker-payload chemistry and dual-payload ADC design.

Bispecific Antibodies

PD-1/VEGF bispecifics are the defining innovation — ivonescimab (developed by Akeso, licensed to Summit Therapeutics) is the lead example. A second wave of PD-L1/VEGF, PD-1/HER2, and EGFR combinations is in active development across dozens of Chinese companies.

GLP-1 & Metabolic

Oral GLP-1 small molecules, triple agonists (GLP-1/GIP/GCG), and extended half-life peptide variants. China's massive T2D patient population drives unmatched clinical enrollment speed and pharmacokinetic optimization capabilities.

CAR-T / Cell Therapy

Autoimmune CAR-T is China's emerging breakthrough area. Building on the first CD19 CAR-T results in SLE from Erlangen, Germany (2021-2022), Chinese groups are generating some of the largest autoimmune CAR-T datasets. Solid tumor CAR-T programs are earlier but represent a significant pipeline.

Oncology (NSCLC, HCC, Gastric)

China's massive patient population in NSCLC, hepatocellular carcinoma, and gastric cancer provides unmatched clinical trial depth. Chinese companies have first-mover data in multiple subsets that Western companies lack access to.

The ADC Leadership Gap

China's strength in ADC chemistry is structural, not cyclical. Building on the first topoisomerase I payload ADCs — Daiichi Sankyo’s Enhertu and Immunomedics’ Trodelvy — Chinese labs moved fast on next-generation TOP1 payloads, highly stable linkers, and bispecific and dual-payload designs. For any BD team building an oncology pipeline in 2026, China is the mandatory first stop for ADC scouting.

Due Diligence Framework: The Three Pillars

Standard pharmaceutical due diligence frameworks, designed for Western asset evaluation, are insufficient for Chinese biotech assets. The risks are different in character, distribution, and detectability. At Vision Lifesciences, we apply a "Three Pillars" due diligence framework specifically designed for the China cross-border context.

Pillar 1 — Data Integrity

Clinical data generated in China must be verified for cross-border regulatory compatibility before any licensing investment decision. The key requirements are:

ICH GCP compliance: Confirm that clinical operations followed the Good Clinical Practice standard in force when each trial ran — ICH E6(R2), or E6(R3), which FDA finalized in September 2025.
FDA acceptance of foreign data: FDA accepts foreign studies not run under an IND if they followed GCP, including independent ethics committee review and informed consent, and FDA can validate the data through an on-site inspection if needed (21 CFR 312.120). There is no hospital-tier test, but sites should be registered clinical trial institutions under NMPA’s record-filing system.
FDA cross-compatibility audit: Review source documents, data management systems, and statistical analysis plans for FDA IND compatibility. Gaps can be remediated but cost time and capital.
Human genetic resources (HGR) compliance: Clinical data and samples from Chinese patients fall under China’s human genetic resources rules, administered by the National Health Commission since May 2024. International collaborations and providing HGR information abroad require filings or approvals, with a security review in specified cases, so confirm the licensor’s HGR record before signing.

Pillar 2 — CMC & Manufacturing

Chemistry, Manufacturing, and Controls (CMC) is where Chinese assets most frequently face Western market entry barriers. The core questions are:

Technology transfer feasibility: Can the manufacturing process be transferred to a Western-compliant CDMO without loss of biological equivalence? Some Chinese biotech processes are highly proprietary and transfer-resistant.
BIOSECURE Act CDMO check: Is the Chinese licensor's current CMO a designated biotechnology company of concern, or likely to become one? Coverage comes from the Pentagon’s 1260H list (BGI and MGI, for example) and an OMB list due by December 18, 2026. WuXi AppTec was added to the 1260H list in June 2026, but a federal court blocked the designation in August 2026; WuXi Biologics has not been designated. For licensees with federal exposure, a tech transfer away from a designated CMO is a commercial precondition.
Analytical method validation: Confirm that analytical methods meet FDA/EMA submission standards. Chinese internal methods often require re-validation to ICH Q2 standards for Western submissions.
Commercial-scale scalability: Assess whether the current manufacturing process can be scaled to commercial volumes (10,000L+ bioreactors for biologics) without material process changes that would require additional regulatory bridging.

Pillar 3 — IP & Freedom to Operate

Intellectual property risk in Chinese assets has a unique profile that differs substantially from Western IP due diligence. Key areas of scrutiny:

CNIPA patent landscape: Conduct a comprehensive analysis of the Chinese patent database for the target compound, combination, and method-of-use claims. The CNIPA filing system has material differences from USPTO that require specialist analysis.
"Improvement patents" risk: A critical China-specific hazard. Some Chinese originators file continuation and improvement patents that could restrict the licensee's ability to optimize or formulate the asset in Western markets. These must be identified and addressed in the license agreement.
Global FTO from day one: Freedom-to-Operate analysis should cover US, EU, and Japan from the outset — not just China. Initiating FTO analysis after term sheet signing is a common mistake that can delay deal close by months.
Technology transfer export controls: China's export control laws (implemented from 2020 onward) may restrict transfer of certain dual-use biotechnologies. Legal counsel with specific China export control expertise is required to assess this risk for each asset class.

Deal Structuring for China In-Licensing

The deal architecture for China-origin in-licensing has evolved significantly as both sides have become more sophisticated. The era of simple territory licenses with flat milestones is giving way to complex, multi-layered structures that balance risk distribution, data-sharing obligations, and manufacturing strategy. For a full clause-by-clause guide, see our cross-border licensing term sheet guide.

Territory Split: The Greater China Model

The dominant deal structure in 2026: the Chinese licensor retains Greater China rights (mainland, Hong Kong, Macau, and Taiwan) and licenses Rest of World (ROW) to the Western partner. This model allows the originator to manage the NMPA regulatory process locally, handle NRDL negotiations, and run its own commercial operation in China — while the licensee gains access to the high-value FDA/EMA regulatory pathways. GSK’s 2025 agreements with Hengrui, for example, cover the world outside mainland China, Hong Kong, Macau, and Taiwan.

Financial Structure: Low Upfront, Milestone-Heavy

Indicatively, upfront payments for Chinese Phase I/II assets run in the tens of millions of dollars, typically below equivalent Western assets, although headline deals have paid far more ($500M for GSK–Hengrui and $1.25B for Pfizer–3SBio, both in 2025). The economic center of gravity sits in the milestone stack — IND filing, Phase 2 initiation, NDA filing, FDA approval, and tiered commercial milestones — and across all biopharma licensing, upfronts averaged about 7% of total deal value in 2025 (J.P. Morgan). Total deal values of $500M to $2B+ are achievable for best-in-class assets even with modest upfronts, with tiered royalties on ROW net sales.

The "NewCo" Joint Vehicle Model

An emerging and increasingly popular structure involves creating a NewCo to hold ex-China rights to the asset. The Chinese originator licenses the asset to a newly formed company, usually incorporated in Delaware or the Cayman Islands and backed by US venture or private-equity investors, and takes equity in it. The structure aligns incentives, brings in third-party capital, and provides a cleaner path to IPO or acquisition: Hengrui licensed its GLP-1 portfolio into Kailera Therapeutics, which went public in April 2026.

Data Sharing and Manufacturing Rights

Modern China in-licensing term sheets explicitly address two critical operational matters: data sharing and manufacturing control. Data sharing clauses govern how Chinese Phase I/II clinical data can be used by the Western partner for FDA IND filings — including which data can be cross-referenced, in what format, and subject to what HGRAC restrictions. Manufacturing rights clauses define who controls the CMC process, who leads technology transfer to a Western-compliant CDMO, and at whose cost — a material commercial consideration, since a full tech transfer can run to millions or tens of millions of dollars.

Technology Export Rules

A license from a mainland Chinese licensor is a technology export. It typically needs a technology-export contract registration with MOFCOM, or a license for restricted technologies, under China’s Technology Import and Export Administration Regulations, while the license fees themselves are processed through banks as current-account receipts. Build the registration step into the closing timeline and confirm with PRC counsel whether the asset’s technology is restricted. Many experienced deal teams use Hong Kong holding entities as the licensor vehicle.

NMPA Data to FDA Acceptance: Regulatory Pathways

The most important regulatory question in any China in-licensing deal is simple: can the Chinese clinical data support US and European regulatory submissions? The answer is increasingly "yes" — but only with deliberate design from the outset. See our detailed guides on the NMPA drug approval process and China clinical trial advantages for global pharma for full regulatory context.

Multi-Regional Clinical Trial (MRCT) Design

The gold standard for China-origin assets targeting global approval is MRCT design from Phase I or Phase II onward. Including Chinese clinical sites within a global trial framework from the start means that the resulting data package supports simultaneous NDA submissions to the FDA, EMA, and NMPA. The NMPA's adoption of ICH E17 guidelines for MRCT design has made this approach increasingly feasible. Western in-licensees who receive Chinese assets mid-development can sometimes retrospectively integrate Chinese data into global dossiers — but this requires careful regulatory alignment and is significantly more complex than prospective MRCT design.

Bridging Study Model

For assets where MRCT design was not implemented from the start, the bridging study model is the most common FDA pathway. Chinese Phase I pharmacokinetic and safety data supports a US IND, enabling the licensee to initiate a US/global Phase II or Phase III without repeating full Phase I in a Western population. The FDA's acceptance of this approach varies by modality — biologics with well-characterized PK/PD profiles are more straightforward than novel small molecules. Pre-IND meetings with FDA, initiated before the licensing deal closes, are essential to validate the bridging strategy early.

FDA 505(b)(1) vs. 505(b)(2)

A licensee with contractual rights of reference to the licensor's data normally files a full 505(b)(1) NDA for a new small molecule, using the Chinese studies directly. The 505(b)(2) pathway applies only when an application relies on studies not conducted by or for the applicant and to which it has no right of reference, such as published literature (21 CFR 314.3). Either way, FDA assesses the foreign data under 21 CFR 312.120 and 314.106, so the Chinese NDA package can form a core part of the US submission. Biological products follow the 351(a) BLA route (or 351(k) for biosimilars).

Pre-IND Meeting Strategy

The single most important regulatory action Western in-licensees should take is requesting an FDA pre-IND meeting before the licensing transaction closes — or at minimum before the term sheet is signed. This meeting establishes FDA's position on the Chinese data package, the bridging study design, and any manufacturing concerns. Using the pre-IND meeting outputs as part of deal due diligence reduces post-signing regulatory risk materially and can prevent scenarios where a multi-hundred-million-dollar upfront payment is followed by an unexpected FDA rejection of the data package.

BIOSECURE Act Compliance for In-Licensing

The BIOSECURE Act — signed into US law on December 18, 2025 — is the most significant piece of US legislation affecting cross-border biopharma since FDAMA. For Western companies in-licensing Chinese biotech assets, understanding what the BIOSECURE Act does — and critically, what it does not — restrict is essential. We analyze the full implications in our dedicated BIOSECURE Act pharmaceutical impact guide.

What BIOSECURE Restricts

US federal agencies buying biotechnology equipment or services from a designated "biotechnology company of concern"
Federal contracts, grants, and loans to companies that use such equipment or services in the federally funded work
Designated companies: biotech companies on the Pentagon’s 1260H list (such as BGI and MGI) and any that OMB designates (first list due by December 18, 2026); the law itself names none

What BIOSECURE Does NOT Restrict

In-licensing transactions and IP transfers from Chinese biotech companies
Use of Chinese clinical data in FDA submissions
CRO partnerships for clinical operations, data management, and biostatistics with companies that are not designated
Equity investments in Chinese biotech companies
Collaborations with Chinese CDMOs that are not designated
Companies with no US federal contracts, grants, or loans

The practical BIOSECURE compliance requirement for in-licensing deals is a CDMO audit at due diligence. If the Chinese licensor's current manufacturing partner is designated, or at risk of designation, and the licensee has federal exposure, the deal should include an explicit tech transfer obligation and timeline as a closing condition or post-closing covenant. The prohibitions are expected to apply from around 2028, with up to five years of grandfathering for existing contracts. The cost and timeline of tech transfer to other CDMOs — such as Samsung Biologics (Korea), Lonza (Switzerland), or FUJIFILM Biotechnologies (US/Japan/Europe) — should be modeled into the deal economics before term sheet signing; see our CDMO market analysis.

BIOSECURE Is a Manufacturing Question, Not a Licensing Question

The most common misconception among Western BD teams is that BIOSECURE restricts in-licensing from China broadly. It does not. It restricts federally funded work with a specific set of designated companies. A clean CDMO check during due diligence, followed by a well-structured tech transfer plan if needed, resolves BIOSECURE compliance for the vast majority of in-licensing transactions.

How Vision Lifesciences Supports Cross-Border Scouting

Vision Lifesciences operates at the intersection of Chinese biotech innovation and Western pharmaceutical business development. Our in-licensing advisory practice is built around four core capabilities that address the specific challenges of China cross-border asset acquisition.

Proprietary Pipeline Scouting

Our Hong Kong and Shanghai teams provide access to pre-publication Chinese pipeline data and early-stage partnering opportunities that are invisible to international BD teams relying solely on conference attendance and commercial databases. We have established relationships with founders, Chief Scientific Officers, and BD leads at over 200 Chinese biotech companies across ADC, bispecific, GLP-1, and cell therapy focus areas.

Technical Due Diligence

We perform the full Three Pillars due diligence framework: data integrity audits against ICH GCP and human genetic resources requirements, CMC technology transfer assessments, BIOSECURE CDMO checks, and global FTO analysis including CNIPA patent landscape review. Our due diligence reports are structured for internal investment committee presentations and external legal review.

Deal Structuring & Term Sheet Negotiation

We support term sheet construction, milestone schedule optimization, royalty benchmarking, territory split structuring, and data sharing clause design. Our team has benchmarked hundreds of cross-border China licensing transactions and brings negotiation experience from both sides of the table — as advisors to both Western licensees and Chinese licensors.

Regulatory Strategy

We prepare NMPA data strategy assessments for FDA pre-IND meeting submissions, advise on MRCT design and bridging study feasibility, and support FDA pre-IND meeting preparation. Our regulatory advisory work typically begins six to twelve months before a deal closes to ensure that regulatory risk is fully quantified before capital is committed.

Frequently Asked Questions

What does in-licensing from China mean?

In-licensing from China means acquiring the rights to a Chinese biotech company's drug asset — typically for development and commercialization outside China. The Chinese company (licensor) retains its domestic rights while the Western partner (licensee) gains the rights to develop, manufacture, and sell the drug in specified territories such as the US, EU, and Japan.

What therapeutic areas are Chinese biotechs strongest in?

Chinese biotechs are a leading source of Antibody-Drug Conjugates (ADCs): China-origin ADCs feature in many of the largest recent licensing deals, and China-origin assets of all types made up 51% of big pharma licensing deals with at least $50 million upfront through Q3 2026 (J.P. Morgan). They are also highly competitive in bispecific antibodies (particularly PD-1/VEGF combinations), GLP-1 and metabolic disease assets, CAR-T cell therapies (including autoimmune applications such as SLE), and oncology broadly — particularly NSCLC, HCC, and gastric cancer.

Does the BIOSECURE Act prevent in-licensing from China?

No. The BIOSECURE Act, signed into law on December 18, 2025, works through US federal procurement, contracts, grants, and loans: it bars federally funded work that uses biotechnology equipment or services from designated "biotechnology companies of concern." The enacted law names no companies; coverage comes from the Pentagon’s 1260H list (for example BGI and MGI) and an OMB list due by December 18, 2026. It does NOT restrict IP licensing deals, the use of Chinese clinical data, or equity investments. Western companies can in-license Chinese biotech assets, but those with federal exposure should make sure that federally funded manufacturing and services do not use a designated company.

How much does it cost to in-license a China biotech asset?

Upfront payments vary widely with stage and competition. Many deals pay tens of millions of dollars upfront, while headline deals have reached $500 million (GSK–Hengrui, 2025) and $1.25 billion (Pfizer–3SBio, 2025). Milestones make up most of the headline value: across all biopharma licensing, upfront payments averaged about 7% of total deal value in 2025 (J.P. Morgan). Chinese assets have historically commanded lower upfronts than comparable Western assets, but that "China discount" is narrowing as data quality and deal precedents improve.

What is a "Greater China rights" deal structure?

In a Greater China rights deal, the Chinese licensor retains commercial and development rights in Greater China (mainland China, Hong Kong, Macau, and Taiwan), while the licensee acquires global ex-China rights (Rest of World, often including the US, EU, Japan, and other markets). This is the most common structure in cross-border China biotech deals; GSK’s 2025 deal with Hengrui, for example, covers the world outside mainland China, Hong Kong, Macau, and Taiwan.

How do I verify Chinese clinical data quality?

Verifying Chinese clinical data quality requires a multi-step approach: confirm that the trials followed GCP, with independent ethics committee review and informed consent, and that FDA could validate the data by on-site inspection, which is what FDA requires to accept foreign studies not run under an IND (21 CFR 312.120); conduct a GCP audit against the ICH standard in force when the trial ran (E6(R2), or E6(R3) from 2025); check human genetic resources (HGR) filings and approvals for any data or samples sent abroad; cross-reference source documents against submitted data packages; and assess whether the data package can support an FDA IND or pre-IND meeting without additional bridging studies.

Find your next China biotech asset with Vision Lifesciences

Our cross-border BD team combines in-country scouting presence in Shanghai and Hong Kong with deep technical due diligence and deal structuring expertise. Let us identify, evaluate, and help you close the Chinese biotech asset that fits your pipeline strategy.

Sources

Need expert guidance on your next deal?

Our team of life sciences advisors can help you navigate complex transactions, from early-stage licensing to full M&A.